JP2019536763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536763A5 JP2019536763A5 JP2019522993A JP2019522993A JP2019536763A5 JP 2019536763 A5 JP2019536763 A5 JP 2019536763A5 JP 2019522993 A JP2019522993 A JP 2019522993A JP 2019522993 A JP2019522993 A JP 2019522993A JP 2019536763 A5 JP2019536763 A5 JP 2019536763A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound according
- formula
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KNCWSXRTKLTULH-MRXNPFEDSA-N C[C@H](CN(CCC1)C(c(cc(c(C)c2)Sc3cnc(NC(C4CC4)=O)[s]3)c2OC)=O)N1C(C=C)=O Chemical compound C[C@H](CN(CCC1)C(c(cc(c(C)c2)Sc3cnc(NC(C4CC4)=O)[s]3)c2OC)=O)N1C(C=C)=O KNCWSXRTKLTULH-MRXNPFEDSA-N 0.000 description 1
- NEBMYACTWBBOTE-NCELDCMTSA-N Cc(c(Sc1cnc(NC(C2CC2)=O)[s]1)c1)cc(OC)c1C(N(CCN1C(C=C)=O)C/C1=N\C)=O Chemical compound Cc(c(Sc1cnc(NC(C2CC2)=O)[s]1)c1)cc(OC)c1C(N(CCN1C(C=C)=O)C/C1=N\C)=O NEBMYACTWBBOTE-NCELDCMTSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022184820A JP2023029752A (ja) | 2016-11-03 | 2022-11-18 | インターロイキン－２誘導性ｔ細胞キナーゼを調節する化合物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417083P | 2016-11-03 | 2016-11-03 | |
| US62/417,083 | 2016-11-03 | ||
| PCT/US2017/059871 WO2018089261A2 (en) | 2016-11-03 | 2017-11-03 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184820A Division JP2023029752A (ja) | 2016-11-03 | 2022-11-18 | インターロイキン－２誘導性ｔ細胞キナーゼを調節する化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536763A JP2019536763A (ja) | 2019-12-19 |
| JP2019536763A5 true JP2019536763A5 (enExample) | 2020-12-17 |
| JP7236996B2 JP7236996B2 (ja) | 2023-03-10 |
Family
ID=62109599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522993A Active JP7236996B2 (ja) | 2016-11-03 | 2017-11-03 | インターロイキン－２誘導性ｔ細胞キナーゼを調節する化合物及び方法 |
| JP2022184820A Pending JP2023029752A (ja) | 2016-11-03 | 2022-11-18 | インターロイキン－２誘導性ｔ細胞キナーゼを調節する化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184820A Pending JP2023029752A (ja) | 2016-11-03 | 2022-11-18 | インターロイキン－２誘導性ｔ細胞キナーゼを調節する化合物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11008314B2 (enExample) |
| EP (1) | EP3534899B1 (enExample) |
| JP (2) | JP7236996B2 (enExample) |
| KR (1) | KR102540515B1 (enExample) |
| CN (1) | CN110099684B (enExample) |
| AU (1) | AU2017358901B2 (enExample) |
| CA (2) | CA3278142A1 (enExample) |
| DK (1) | DK3534899T3 (enExample) |
| ES (1) | ES2926153T3 (enExample) |
| IL (1) | IL266181B2 (enExample) |
| MX (1) | MX392031B (enExample) |
| PT (1) | PT3534899T (enExample) |
| WO (1) | WO2018089261A2 (enExample) |
| ZA (1) | ZA201903071B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| PT3534899T (pt) * | 2016-11-03 | 2022-07-07 | Corvus Pharmaceuticals Inc | Compostos e métodos de modulação da cinase de células t induzível por interleucina-2 |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| AU2019364417A1 (en) * | 2018-10-24 | 2021-05-20 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis |
| US20230029266A1 (en) * | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2021297778A1 (en) | 2020-06-23 | 2022-11-24 | Dana-Farber Cancer Institute, Inc. | Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use |
| CN114605404B (zh) * | 2022-03-23 | 2024-01-05 | 合肥美诺医药有限公司 | 一种新型含噻唑类化合物、中间体及其应用 |
| CN114621213B (zh) * | 2022-03-23 | 2023-12-08 | 合肥美诺医药有限公司 | 含噻唑类化合物及其中间体与应用 |
| KR20240169633A (ko) * | 2022-04-05 | 2024-12-03 | 코버스 파마슈티칼스, 인크. | Th1 세포 활성을 증가시키기 위한 itk 저해제 |
| WO2025085889A1 (en) * | 2023-10-20 | 2025-04-24 | Corvus Pharmaceuticals, Inc. | Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses |
| WO2025171035A1 (en) * | 2024-02-06 | 2025-08-14 | Corvus Pharmaceuticals, Inc. | Itk inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| BR0212101A (pt) * | 2001-08-24 | 2004-08-24 | Pharmacia & Up John Company | 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças |
| US7973169B2 (en) * | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US8222285B2 (en) | 2007-06-11 | 2012-07-17 | Bristol-Myers Squibb Company | 1,3-dihydroxy substituted phenylamide glucokinase activators |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| US9649313B2 (en) | 2012-11-26 | 2017-05-16 | The University Of North Carolina At Chapel Hill | Use of ITK inhibitors for the treatment of cancer |
| CN105164112B (zh) | 2013-01-31 | 2017-10-13 | 中国科学院上海药物研究所 | 酰胺类化合物及其制备方法、药物组合物和用途 |
| CA2965178C (en) | 2014-10-22 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| EP3197836A1 (en) * | 2014-11-19 | 2017-08-02 | Hach Lange GmbH | Control of wastewater treatment based on regulatory period |
| CN105884711A (zh) | 2014-12-16 | 2016-08-24 | 中国药科大学 | 噻唑类化合物、其制备方法及其在制药中的用途 |
| WO2017044858A2 (en) * | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| PT3534899T (pt) * | 2016-11-03 | 2022-07-07 | Corvus Pharmaceuticals Inc | Compostos e métodos de modulação da cinase de células t induzível por interleucina-2 |
-
2017
- 2017-11-03 PT PT178687299T patent/PT3534899T/pt unknown
- 2017-11-03 KR KR1020197015471A patent/KR102540515B1/ko active Active
- 2017-11-03 WO PCT/US2017/059871 patent/WO2018089261A2/en not_active Ceased
- 2017-11-03 US US16/346,360 patent/US11008314B2/en active Active
- 2017-11-03 DK DK17868729.9T patent/DK3534899T3/da active
- 2017-11-03 CA CA3278142A patent/CA3278142A1/en active Pending
- 2017-11-03 EP EP17868729.9A patent/EP3534899B1/en active Active
- 2017-11-03 CN CN201780079068.5A patent/CN110099684B/zh active Active
- 2017-11-03 ES ES17868729T patent/ES2926153T3/es active Active
- 2017-11-03 CA CA3042252A patent/CA3042252C/en active Active
- 2017-11-03 IL IL266181A patent/IL266181B2/en unknown
- 2017-11-03 MX MX2019005076A patent/MX392031B/es unknown
- 2017-11-03 JP JP2019522993A patent/JP7236996B2/ja active Active
- 2017-11-03 AU AU2017358901A patent/AU2017358901B2/en active Active
-
2019
- 2019-05-16 ZA ZA2019/03071A patent/ZA201903071B/en unknown
-
2021
- 2021-04-07 US US17/224,410 patent/US11897874B2/en active Active
-
2022
- 2022-11-18 JP JP2022184820A patent/JP2023029752A/ja active Pending
-
2024
- 2024-02-12 US US18/439,695 patent/US12686677B2/en active Active
-
2026
- 2026-03-17 US US19/569,194 patent/US20260209216A1/en active Pending